CRDF News and Press, Cardiff Oncology Inc. From 03/03/21

Cardiff Oncology to Present at H.C. Wainwright Global Life Sciences Conference PR Newswire SAN DIEGO , March 3, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage biotechnology company developing drugs to treat cancers with the...

Cardiff Oncology (CRDF): Q4 GAAP EPS of -$0.19 misses by $0.05.Revenue of $0.12M (+33.3% Y/Y) beats by $0.09M.Press Release For further details see: Cardiff Oncology EPS misses by $0.05, beats on revenue

Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights PR Newswire SAN DIEGO , Feb. 25, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cance...

Cardiff Oncology is a single-asset company focused on developing a PLK1 inhibitor called onvansertib. PLK1 inhibitors have a poor history in the clinic, but Cardiff believes their patient-targeted approach and therapeutic combination regime can overcome past failures. Previously r...

Cardiff Oncology to Participate in Gastrointestinal (GI) Oncology and Pancreatic Cancer Panel Discussion at the Cowen 41st Annual Health Care Conference PR Newswire SAN DIEGO , Feb. 24, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinic...

Cardiff Oncology to Present at the LifeSci Partners Precision Oncology Day PR Newswire SAN DIEGO , Feb. 16, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing a drug to treat cancers with the gr...

Cardiff Oncology Presents Phase 2 mCRPC Trial Data Showing a Two-Fold Increase in Efficacy with an Optimized Onvansertib Dosing Schedule - Two-fold increase (29% to 63%) in disease control rate at 12 weeks (the trial's primary efficacy endpoint) seen in patients receiving onvans...

NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr. Th...

Cardiff Oncology (NASDAQ: CRDF) is an oncology specialist that had a fantastic year in 2020. The market is excited about the biotech's lead molecule, onvansertib, because it might work to defeat cancer caused by the KRAS mutation, a significant market opportunity. Healthcare bureau ...

Are These Top Biotech Stocks On Your Watchlist? 3 In Focus During a pandemic, the healthcare industry would normally be in the spotlight. Because of this, we have seen biotech stocks become the top performers on the stock market . Throughout 2020, many biotech companies shif...